Guggenheim Securities named ABIVAX its top biotechnology pick following first-half 2026 earnings. The firm reiterated a Buy rating for the stock. Guggenheim established a price target of $175 per share.
ABIVAX maintains pro-forma cash of €1.2 billion. This capital provides a cash runway through the fourth quarter of 2029.
Regulators shared positive pre-NDA feedback regarding the lead drug candidate, obefazimod. The company plans to select a combination candidate by the end of 2026. ABIVAX expects to start a clinical program for the candidate by early 2028.